The FDA recently approved the first eyedrop to treat age-related nearsightness due to poor accommodation, a disorder experienced by more than 100 million Americans. Spoiler alert . . . its pilocarpine eye drops -  which have been on the market for over 70 years.  What does the data say about this new formulation of an old drug and its ability to help with age-related presbyopia? Listen in for a discussion on efficacy and cost.

Redeem your CPE or CME credit here!

• Pharmacist members
• CME

Need a membership?

• Join for CPE Credit 
• Join for CME Credit 

References and resources: 

1. https://www.ophthalmologytimes.com/view/fda-approves-eye-drops-for-treatment-of-presbyopia
2. https://clinicaltrials.gov/ct2/show/NCT04657172

Continuing Education Information:

Learning Objectives: 

1. Describe the evidence that informed the FDA's decision to approve a new formulation of pilocarpine for presbyopia

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-040-H01-P
Initial release date: 01/10/22
Expiration date: 01/10/2023
Additional CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram